subscribeSubscribe
Combo drugs: latest trend in local pharmaceuticals

Combo drugs: latest trend in local pharmaceuticals
Lee Hye-seon KOREAMED
19 Aug 2019
Share Share
U.S. FDA Approves GATTEX® for Children 1Y Age&Older With Short Bowel Syndrome

U.S. FDA Approves GATTEX® for Children 1Y Age&Older With Short Bowel Syndrome
PR NEWSWIRE
17 May 2019
Share Share
Shire Moves to Protect Gattex From Par Generic Challenge

Shire Moves to Protect Gattex From Par Generic Challenge
BLOOMBERG
31 Jul 2018
Share Share
Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.

Gattex (teduglutide), Amlodipine and Valsartan Tabs : Shire-NPS Pharm v. Par Pharma et al.
PATENT LITIGATION
30 Jul 2018
Share Share
SMC endorses five new therapies for NHS Scotland

SMC endorses five new therapies for NHS Scotland
Selina McKee PHARMA TIMES
10 Apr 2018
Share Share
FDA Confirms Paragraph IV Patent Challenge of Gattex (Teduglutide) Injection

FDA Confirms Paragraph IV Patent Challenge of Gattex (Teduglutide) Injection
FDA
03 Mar 2018
Share Share
NICE turns down Shire’s Revestive for bowel condition

NICE turns down Shire’s Revestive for bowel condition
Selina McKee PHARMA TIMES
14 Nov 2017
Share Share
Gattex (Teduglutide): Shire-NPS Pharma v. AmbioPharm & Par Pharmaceutical

Gattex (Teduglutide): Shire-NPS Pharma v. AmbioPharm & Par Pharmaceutical
PATENT LITIGATION
10 Apr 2017
Share Share
Shire Receives Extension of Market Authorization in Europe for Revestive

Shire Receives Extension of Market Authorization in Europe for Revestive
PR NEWSWIRE
07 Jul 2016
Share Share
Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide)

Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide)
PR NEWS WIRE
27 May 2016
Share Share